A recent investigation highlights ongoing concerns over infant formula safety, revealing regulatory shortcomings and the continued threat to vulnerable infants amid unresolved outbreaks and stalled legislation.
A recent Spotlight on America report has renewed attention on two infant formula botulism outbreaks and on what federal regulators knew before the illnesses surfaced. The investigation, by Lisa Fletcher, Andrea Nejman and Nathan Aaron, examined the ByHeart Whole Nutrition outbreak, which the CDC said involved 48 babies across 17 states, as well as a later outbreak tied to Nara Organics formula.
The reporting landed after both recalls had already run their course, a stage at which most newsrooms would typically have moved on. Yet the programme pressed ahead, asking whether Congress might still hold hearings and checking the status of the Infant Formula Safety Modernization Act. Reuters-style records review showed the bill had not advanced to markup or a floor vote after its hearing in late April, leaving the legislation stalled despite the continuing fallout from the outbreaks.
The report also centred the experience of parents, including Amy Mazziotti, who said she repeatedly asked doctors whether formula could have been the cause of her son’s illness and felt dismissed when they told her there was no way it could be. Months later, the ByHeart products were recalled nationwide. Her point was stark: a child surviving does not mean the family has escaped harm.
Federal health agencies have said the Nara outbreak remains under investigation. The CDC said in June that three infants in California, Pennsylvania and Washington were hospitalised after consuming the formula and were treated with BabyBIG®, the approved therapy for infant botulism. By early July, the CDC and FDA said four infants had been confirmed ill and warned parents not to feed the recalled product to children. In the ByHeart case, the CDC said in November 2025 that 28 confirmed and 20 probable cases had been identified, and that all products had been recalled while investigators continued to look for the source.
At the heart of the criticism is a wider regulatory gap. The FDA’s finished powdered infant formula testing rules still focus on two organisms, and Clostridium botulinum is not among them. The agency says it is still working to identify the root cause of both outbreaks, even though the organism had already been flagged in an earlier warning to industry. For the parents affected, and for the journalists who kept reporting after the news cycle had faded, the question remains the same: how many warnings are enough before action follows?
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
